Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 1/20 | 0.42 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8021171 | 1.00 | USP1 (0.42) | USP1WDR48POLBCYP2D6MAOB | |
| SCHEMBL7219023 | 1.00 | USP1 (0.42) | USP1WDR48POLBCYP2D6MAOB | |
| SCHEMBL14543852 | 0.86 | USP1 (0.42) | USP1WDR48MAOBALDH1A1SMN1; SMN2 | |
| SCHEMBL7221650 | 0.85 | PDCD1 (0.42) | USP1WDR48MAOBALDH1A1MAPT | |
| SCHEMBL8036861 | 0.85 | TSHR (0.56) | USP1WDR48CYP2D6ALDH1A1SMN1; SMN2 | |
| SCHEMBL8036865 | 0.85 | TSHR (0.56) | USP1WDR48CYP2D6ALDH1A1SMN1; SMN2 | |
| SCHEMBL29101714 | 0.83 | USP1 (0.47) | USP1WDR48MAOBMMP9 | |
| SCHEMBL6427211 | 0.83 | USP1 (0.47) | USP1WDR48MAOBMMP9 | |
| SCHEMBL5968665 | 0.83 | USP1 (0.47) | USP1WDR48MAOBMMP9 | |
| SCHEMBL5160271 | 0.83 | USP1 (0.47) | USP1WDR48MAOBMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6583292-B2 | Admixing an oxazole derivative with a base and a compound composed of an alcohol and/or an alkoxide | EMORY UNIVERSITY | 2003-06-24 | — | — | US | disclosed |
| US-20020087026-A1 | Methods for the esterification of alcohols and compounds useful therefor as potential anticancer agents | EMORY UNIVERSITY | 2002-07-04 | — | — | US | disclosed |
| US-6399783-B1 | CHEMICAL INTERMEDIATE FOR TAXOL | EMORY UNIVERSITY | 2002-06-04 | — | — | US | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| US-6150537-A | Methods for the esterification of alcohols and compounds useful therefor as potential anticancer agents | EMORY UNIVERSITY (US) | 2000-11-21 | — | — | US | disclosed |
| EP-1040105-A2 | METHODS FOR THE ESTERIFICATION OF ALCOHOLS AND COMPOUNDS USEFUL THEREFOR AS POTENTIAL ANTICANCER AGENTS | EMORY UNIVERSITY (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6127546-A | Process for the preparation of oxazoline compound | DONG KOOK PHARMACEUTICAL CO., LTD. (KR) | 2000-10-03 | — | — | US | disclosed |
| US-6020174-A | (2R,3S)- AND (2S,3R)-ENANTIOMERS OF TRANS-.BETA.-PHENYLGLYCIDIC ESTERS, PREPARED BY LIPASE-MEDIATED ENANTIOSELECTIVE TRANSESTERIFICATION, ARE USED FOR THE SYNTHESIS OF THE TAXOL C-13 SIDE CHAIN | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999031079-A2 | METHODS FOR THE ESTERIFICATION OF ALCOHOLS AND COMPOUNDS USEFUL THEREFOR AS POTENTIAL ANTICANCER AGENTS | EMORY UNIVERSITY (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020087026-A1 | Methods for the esterification of alcohols and compounds useful therefor as potential anticancer agents | FAR1, ADH1A, ADH1C | USP1 3653/4885WDR48 3525/4885POLB 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.